Latest Product Launches News

Ricegrowers Limited (SunRice) reported a 3.7% rise in profit after tax for FY25 despite a 1.5% decline in revenue, driven by strategic cost savings and product innovation. The company announced a fully franked 50 cent final dividend and reactivated its Dividend Reinvestment Plan.

Xero Limited has announced a binding agreement to acquire Melio Limited for US$2.5 billion, backed by a fully underwritten A$1.85 billion equity raise. This strategic move aims to accelerate Xero’s US growth and more than double its FY25 revenue by FY28.

The Calmer Co. International Limited has launched its Taki Mai kava tinctures on Amazon USA, marking a strategic expansion into a rapidly growing wellness segment. This move aims to capitalize on the booming US tincture market and strengthen the company’s foothold in natural relaxation products.

Hydralyte USA reported its strongest monthly sales in May 2025, alongside continued improvement in EBITDA losses, signaling steady progress toward profitability.

HighCom Limited has recommissioned its XTclave™ system in Ohio, doubling production capacity and setting the stage for new ballistic product launches in FY26. The move strengthens its collaboration with the U.S. Department of Defense and positions the company for significant government contract opportunities.

Sprintex Limited has boosted its Türkiye presence by extending its exclusive distribution deal, securing a new A$377,000 order, and launching larger Jet Blowers aimed at industrial and municipal markets.

TALi Digital has successfully raised $800,000 through a private placement to fuel the commercialisation of its digital health products aimed at enhancing childhood cognitive attention.

Audeara Limited has reported record unaudited revenue of $3.64 million for the first 11 months of FY25, marking a 14% increase over FY24 and driven by new product launches and international partnerships.

EVE Health Group’s subsidiary Nextract has inked a pivotal two-year agreement with TeleDocs Clinic, enabling nationwide online prescribing of its upcoming erectile dysfunction and dysmenorrhea products ahead of regulatory approval.

Cochlear Limited has lowered its FY25 earnings guidance due to slower-than-expected sales growth and a sharper decline in Services revenue. Despite this, implant unit growth remains on track, driven by emerging markets.

Firebrick Pharma has unexpectedly withdrawn its planned share placement, raising questions about its capital strategy amid ongoing product launches.

Adveritas Limited reports a record 61% increase in annualised recurring revenue, driven by strong gains in sports betting and new product launches, while preparing for a strategic expansion into North America.